<DOC>
	<DOCNO>NCT01263366</DOCNO>
	<brief_summary>This study , nonrandomized open-label Phase I safety exploratory study , evaluate safety topical norepinephrine post-surgical breast cancer patient undergo radiation therapy . The study also provide information whether topical norepinephrine prevent decrease severity radiation dermatitis experience patient .</brief_summary>
	<brief_title>Exploratory Study Norepinephrine Prevent Radiodermatitis Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<criteria>Eligibility Criteria Subjects must : â‰¥ age 18 year age document pathological diagnosis Stage Ia ( T1 , N0 , M0 ) , Stage Ib ( T0 1 , N1mic , M0 ) Stage IIa ( T &lt; 3cm , N0 , M0 ) infiltrate ductal lobular carcinoma breast ductal carcinoma situ ( DCIS ) . postsurgical patient schedule treat least 40 50.4 Gy whole breast axilla use either standard hypofractionated radiation technique . An additional 1016 Gy boost lumpectomy region may also deliver . All radiation treatment deliver base standard CT planning . ability understand inform consent document . able comply protocol schedule . negative serum pregnancy test ( within 7 day prior start radiation therapy ) , female child bear potential . consent utilize medically acceptable method contraception throughout study period childbearing potential . Exclusion Criteria Subjects : unhealed surgical wound scar study treatment area ( axilla ) . underlie active untreated cardiac disease ( e.g . arrhythmia ) . generalize skin disorder require treatment within past 6 month . connective tissue disorder . rash , ulceration , poorly heal scar study drug application area ( axilla ) . know allergy norepinephrine . know uncontrolled hypertension ( repeatedly elevate BP ; systolic BP &gt; 139 diastolic BP &gt; 89 ) . know clinically significant abnormal ECG within past 6 month . receive MAO inhibitor antidepressant ( triptyline imipramine type ) . pregnant breastfeeding . lymphovascular space invasion pathology . dermal lymphatic invasion pathology . proximity tumor overlie skin evidence distance le 5 mm US MRI ( perform ) within 2 cm anticipated application field diagnosis inflammatory breast cancer . receive chemotherapy Herceptin concurrent radiation . previous radiation breast treat .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Radiodermatitis</keyword>
	<keyword>Prevention</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Breast</keyword>
	<keyword>Radiation Dermatitis</keyword>
</DOC>